We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Oculis S.A., (Oculis) a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations, and Accure Therapeutics, a private translational neuroscience R&D company...
AGC Biologics, a global biopharmaceutical contract development and manufacturing organization (CDMO), has entered a partnership with Oculis to manufacture OCS-02, a Phase II investigational drug targeting both Dry Eye Disease and Anterior Uveitis ...
Hoping to push on with its work on next-gen eye treatments, Oculis has raised an extra CHF 15 million ($15.2 million) as it looks to fellow native Swiss biopharma Novartis for its next project....